Halozyme Therapeutics, Inc. vs. Sutro Biopharma, Inc.
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| HALO | STRO | |
|---|---|---|
| Market Cap | $12.23 billion | $420.56 million |
| Revenue (TTM) | $1.66 billion | $99.61 million |
| Net Income (TTM) | $413.60 million | $-153,602,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | STRO | |
|---|---|---|
| P/E Ratio | 30.06 | — |
| Price / Book | 85.21 | -6.29 |
| Price / Sales | 7.35 | 4.22 |
STRO leads on 2 of 2 valuation factors.
Profitability
| HALO | STRO | |
|---|---|---|
| Net Margin | 24.86% | -154.21% |
| Return on Equity | 288.13% | 229.64% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| HALO | STRO | |
|---|---|---|
| Short Interest | 9.79% | 0.07% |
STRO leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, STRO overview, STRO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.